Tofacitinib in patients with ulcerative colitis: Health-related quality of life in phase 3 randomised controlled induction and maintenance studies

Journal of Crohn's and Colitis

Volumn 12, Issue 2, 2018, Pages 145-156

  Panés, Julian ^a   Vermeire, Séverine ^b   Lindsay, James O ^c   Sands, Bruce E ^d   Su, Chinyu ^e   Friedman, Gary ^e   Zhang, Haiying ^e   Yarlas, Aaron ^f   Bayliss, Martha ^f   Maher, Stephen ^f   Cappelleri, Joseph C ^e   Bushmakin, Andrew G ^e   Rubin, David T ^g  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

^f OPTUM   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Patient reported outcomes; Quality of life; Ulcerative colitis

Indexed keywords

PLACEBO; TOFACITINIB; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EMOTION; FEMALE; HUMAN; INTESTINE FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; TREATMENT DURATION; ULCERATIVE COLITIS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; TIME FACTOR;

ADULT; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; JANUS KINASE INHIBITORS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 85041317886     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjx133     Document Type: Article

References (41)

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
2. Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009;21:558-64.
3. Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. Qual Life Res 2008;17:877-86.
4. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm 2014;20:309-14.
5. Sammut J, Scerri J, Xuereb RB. The lived experience of adults with ulcerative colitis. J Clin Nurs 2015;24:2659-67.
6. Jansen F, van Uden-Kraan CF, Braakman JA, van Keizerswaard PM, Witte BI, Verdonck-de Leeuw IM. A mixed-method study on the generic and ostomy-specific quality of life of cancer and non-cancer ostomy patients. Support Care Cancer 2015;23:1689-97.
7. McCormick JB, Hammer RR, Farrell RM, et al. Experiences of patients with chronic gastrointestinal conditions: in their own words. Health Qual Life Outcomes 2012;10:25.
8. Hughes LD, King L, Morgan M, et al. Food-related quality of life in inflammatory bowel disease: development and validation of a questionnaire. J Crohns Colitis 2016;10:194-201.
9. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations [EFCCA] patient survey. J Crohns Colitis 2007;1: 10-20.
10. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:1135-40.
11. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:794-802.
12. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.
13. Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomised trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol 2015;15:14.
14. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
15. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246-56.e6.
16. Food and Drug Administration. Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry. 2016. http://www.fda.gov/downloads/ Drugs/Guidances/UCM515143.pdf Accessed March 28, 2017.
17. Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-Reported Outcomes: Measurement, Implementation and Interpretation. Boca Raton, FL: Chapman & Hall/CRC; 2013.
18. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
19. Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis 2009;15:581-8.
20. Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol 2012;12:108.
21. US Dept of Health, FDA, CDER, CBER, CDRH. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. https://www.fda.gov/ downloads/Drugs/./Guidances/UCM193282.pdf Accessed March 29, 2017.
22. European Medicines Agency. Reflection Paper on the Use of Patient Reported Outcome [PRO] Measures in Oncology Studies. 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2014/06/WC500168852.pdf Accessed March 28, 2017.
23. Medical Research Council. Patient-Reported Outcome Measures [PROMs]: Identifying UK Research Priorities. 2009. https://www.mrc. ac.uk/documents/pdf/patient-reported-outcome-measures-proms-identifying- uk-research-priorities1/ Accessed March 28, 2017.
24. Sandborn WJ, Ghosh S, Panes J, et al.; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
25. Sandborn WJ, Su C, Sands BE, et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36.
26. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol 1989;42:403-8.
27. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
28. Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004;10:261-9.
29. Maruish ME, editor. User's Manual for the SF-36v2® Health Survey. 3rd edn. Lincoln, RI: QualityMetric Inc; 2011.
30. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
31. Van Belle G, Fisher LD, Heagerty PJ, Lumley T. Biostatistics: A Methodology for the Health Sciences. 2nd edn. New York, NY: John Wiley & Sons; 2004.
32. Ware JE Jr. User's Manual for the Sf-36v2 Health Survey. 2nd edn. London: Quality Metric; 2007.
33. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd edn. New York, NY: McGraw-Hill; 1994.
34. Kalafateli M, Triantos C, Theocharis G, et al. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol 2013;26:243-8.
35. Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24:762-9.
36. Feagan BG, Patel H, Colombel JF, et al. Effects of vedolizumab on healthrelated quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther 2017;45:264-75.
37. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3.
38. Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720-7.
39. Baker F, Haffer SC, Denniston M. Health-related quality of life of cancer and noncancer patients in Medicare managed care. Cancer 2003;97:674-81.
40. Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM. A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Clin J Am Soc Nephrol 2010;5:252-60.
41. Pickard AS, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes 2011;9:26.